Business Context and Reporting Period
This Form 6-K filing by Immunocore Holdings Plc, dated March 2, 2023, serves to furnish the Company's 2022 Annual Report and a letter to shareholders. The filing references the Annual Report on Form 20-F for the fiscal year ended December 31, 2022, which was filed with the SEC on March 1, 2023.
Key Financial Metrics
The provided text does not contain specific financial data. It acts as a cover document referencing the Form 20-F for detailed metrics. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this filing text.
Material Changes
No material changes or comparative financial analysis are included in this specific document. The filing solely announces the availability of the 2022 Annual Report.
Guidance, Outlook, and Risks
This document does not provide specific guidance, outlook, management commentary, or risk factors. It notes that a letter to shareholders from the Chief Executive Officer is included in the referenced Annual Report and attached as Exhibit 99.1, but the content of that letter is not summarized in the filing text provided.
Investor Verification Checklist
- Verify the full 2022 Annual Report on Form 20-F filed on March 1, 2023, for detailed financial statements.
- Review Exhibit 99.1 (Company letter to shareholders) for management commentary and strategic updates.
- Confirm the Company's status as a Foreign Private Issuer filing under Form 20-F.